cerivastatin การใช้
- Rhabdomyolysis is suspected of being a side effect of the use of cerivastatin.
- The Spanish agency said another 82 people had suffered adverse reactions to cerivastatin treatment.
- Cerivastatin was withdrawn by its manufacturer in 2001.
- Hospital officials suspected the death might be related to cerivastatin and alerted health authorities Monday.
- Zucchini said the woman hadn't taken Lipobay, but another drug with cerivastatin in it.
- Cerivastatin was voluntarily withdrawn from the market worldwide in 2001, due to reports of fatal rhabdomyolysis.
- Simvastatin and lovastatin are inactive lactones which must be lipophilic cerivastatin has a pyridine-based ring structure.
- CYP3A4 isoenzyme is the most predominant isoform involved in metabolism of lovastatin, simvastatin, atorvastatin and cerivastatin.
- Working with FDA, Bayer voluntarily pulled the drug, also known as cerivastatin, off the market Wednesday.
- The Leverkusen-based company said the deaths occurred following treatment with Lipobay's active ingredient, cerivastatin.
- The Leverkusen-based company said the deaths occurred following treatment with Baycol's active ingredient, cerivastatin.
- The incidence of rhabdomyolyis was 0.44 per 10, 000 patients treated with statins other than cerivastatin.
- The frequency of deadly cases of rhabdomyolysis with cerivastatin was 16 to 80 times higher than with other statins.
- But on Aug . 8, Baycol, also known by the generic name cerivastatin, was taken off the market.
- During postmarketing surveillance, 52 deaths were reported in patients using cerivastatin, mainly from rhabdomyolysis and its resultant renal failure.
- In August 2001, Bayer voluntarily recalled cerivastatin, marketed as Baycol, after 31 people died from rhabdomyolysis caused by the drug.
- Wednesday, working with FDA, Bayer announced it was stopping sales of Baycol, also called cerivastatin, in every country except Japan.
- Pittsburgh-based Bayer has acknowledged the link and said it acted responsibly by withdrawing the drug, known clinically as cerivastatin, in 2001.
- Bayer A . G . added a contraindication for the concomitant use of cerivastatin and gemfibrozil to the package 18 months after the drug interaction was found.
- The most clinically relevant interactions have been associated with the lipid lowering drugs statins, which led to the removal of cerivastatin from the market in 2002.
- ตัวอย่างการใช้เพิ่มเติม: 1 2